Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-024-02171-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Yoshitaka Ono und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. Hauptthemen laut MEDLINE: Endoscopic Mucosal Resection, Rivaroxaban, Pyridones, Pyrazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Promotion Administration, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
The patients taking direct oral anticoagulants (DOACs) are at high risk for developing ischemic stroke and delayed bleeding in upper gastrointestinal endoscopic submucosal dissection (ESD). We aimed to identify the optimal DOAC based on both adverse events in upper gastrointestinal ESD.
Methods
A retrospective population-based cohort study was conducted using the Diagnosis Procedure Combination database in Japan. We included patients on a DOAC undergoing upper gastrointestinal ESD between 2012 and 2021. The primary outcomes were ischemic stroke occurring after upper gastrointestinal ESD and delayed bleeding in gastroduodenal and esophageal ESD. Inverse probability weightings were applied to balance the four DOAC groups (dabigatran, rivaroxaban, apixaban, and edoxaban), and logistic regression analyses were performed to compare the outcomes.
Results
We analyzed 9729 patients on a DOAC undergoing upper gastrointestinal ESD. Ischemic stroke developed after upper gastrointestinal ESD in 1.4%, 0.7%, 0.6%, and 0.8% of patients taking dabigatran, rivaroxaban, apixaban, and edoxaban, respectively, after weighting. Rivaroxaban and apixaban showed significantly lower risk of ischemic stroke compared with dabigatran (odds ratio, 0.15 and 0.12, respectively) in standard doses. The delayed bleeding developed after gastroduodenal ESD in 7.6%, 14.6%, 19.2%, and 17.3% of patients taking each DOAC, respectively, with the lowest risk in dabigatran, followed by rivaroxaban. A similar pattern was observed in delayed bleeding in esophageal ESD (3.2%, 5.4%, 7.5%, and 5.5% in each DOAC), but with no significant results.
Conclusions
Rivaroxaban might be an optimal DOAC for upper gastrointestinal ESD showing a lower risk for both ischemic stroke and delayed bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan.
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. waku-style@festa.ocn.ne.jp.
- Department of Health Administration and Policy, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8575, Japan.
- Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, S1560/S1568 M&D Tower 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
ORCID-Profile: Waku Hatta
Förderung
- Health Promotion Administration, Ministry of Health and Welfare
Zitieren
APA
Ono, Y., Hatta, W., Tarasawa, K., Ogata, Y., Abe, H., Sato, I., Hatayama, Y., Saito, M., Jin, X., Uno, K., Koike, T., Imatani, A., Hamada, S., Fujimori, K., Fushimi, K., & Masamune, A. (2025). Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02171-2
Vancouver
Ono Y, Hatta W, Tarasawa K, Ogata Y, Abe H, Sato I, et al. Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02171-2
BibTeX
@article{Ono2025,
author = {Ono, Yoshitaka and Hatta, Waku and Tarasawa, Kunio and Ogata, Yohei and Abe, Hiroko and Sato, Isao and Hatayama, Yutaka and Saito, Masahiro and Jin, Xiaoyi and Uno, Kaname and Koike, Tomoyuki and Imatani, Akira and Hamada, Shin and Fujimori, Kenji and Fushimi, Kiyohide and Masamune, Atsushi},
title = {Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-024-02171-2}
}
EUVIMED